Literature DB >> 9130659

Fc gamma receptor II dependency of enhanced presentation of major histocompatibility complex class II peptides by a B cell lymphoma.

M Berg1, R Uellner, J Langhorne.   

Abstract

Here we show that the B cell lymphoma A20.292 is capable of enhanced antigen presentation to CD4+ T cells in the presence of specific antibodies. This enhancement was inhibited by anti-Fc gamma receptor (R) antibodies, suggesting that it might be due to preferential uptake of the antigen/antibody complex through the Fc gamma RII receptor. However, immunoprecipitation studies revealed that the FcR of A20.292 cells was of the B cell type, Fc gamma RIIb1, which is not thought to be able to internalize antigen/antibody complexes via clathrin-coated pits. It was considered unlikely that A20.292 had an altered form of the B cell Fc gamma R (RIIb1) receptor that enabled internalization, since similar enhancing effects were also observed using an Fc gamma RII cell line that had been transfected with Fc gamma RIIb1. To reconcile these findings with the expression of Fc gamma RIIb1, it is postulated that immune complexes are concentrated on the cell surface by the Fc gamma RIIb1 and are thus available for preferential uptake by random fluid-phase endocytosis. This results in more efficient generation of the epitopes recognized by these T cell hybridomas.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9130659     DOI: 10.1002/eji.1830270432

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  5 in total

1.  Dendritic cells, but not macrophages or B cells, activate major histocompatibility complex class II-restricted CD4+ T cells upon immune-complex uptake in vivo.

Authors:  Judith M H de Jong; Danita H Schuurhuis; Andreea Ioan-Facsinay; Mick M Welling; Marcel G M Camps; Ellen I H van der Voort; Tom W J Huizinga; Ferry Ossendorp; J Sjef Verbeek; René E M Toes
Journal:  Immunology       Date:  2006-09-21       Impact factor: 7.397

2.  Human monoclonal antibodies targeting nonoverlapping epitopes on insulin-like growth factor II as a novel type of candidate cancer therapeutics.

Authors:  Weizao Chen; Yang Feng; Qi Zhao; Zhongyu Zhu; Dimiter S Dimitrov
Journal:  Mol Cancer Ther       Date:  2012-05-02       Impact factor: 6.261

3.  Specific antigen targeting to surface IgE and IgG on mouse bone marrow-derived mast cells enhances efficiency of antigen presentation.

Authors:  C Tkaczyk; M Viguier; Y Boutin; P Frandji; B David; J Hébert; S Mécheri
Journal:  Immunology       Date:  1998-07       Impact factor: 7.397

4.  Identification of critical residues of linear B cell epitope on Goodpasture autoantigen.

Authors:  Xiao-yu Jia; Zhao Cui; Jian-nan Li; Shui-yi Hu; Ming-hui Zhao
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

5.  Augmenting Vaccine Immunogenicity through the Use of Natural Human Anti-rhamnose Antibodies.

Authors:  Md Kamal Hossain; Abhishek Vartak; Partha Karmakar; Steven J Sucheck; Katherine A Wall
Journal:  ACS Chem Biol       Date:  2018-07-02       Impact factor: 5.100

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.